The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.

Genmab acquires the Dutch biotech for $8bn.

BNT329 enters the clinic, as do four other new ADCs.

Four more failed tiragolumab trials, including Imbrave-152, will feature.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.